Table 2.
Hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between ILTCs, RFS, and endometrial cancer-specific survival by histological subtype, N=295
| ILTCs | RFS1 | ILTCs | EC-specific survival | ||||
|---|---|---|---|---|---|---|---|
| recurrences, n (%)2 | HR (95% CI)3 | HR (95% CI)4 | deaths, n (%)2 | HR (95% CI)3 | HR (95% CI)4 | ||
| Low-grade endometrioid, N=97 | |||||||
| Absent (n=88) | 8 (9.1) | 1.00 | 1.00 | Absent (n=90) | 3 (3.3) | 1.00 | 1.00 |
| Present (n=7) | 1 (14.3) | 1.67 (0.21, 13.38) | 0.60 (0.06, 5.78) | Present (n=7) | 1 (14.3) | 4.61 (0.48, 44.31) | 0.49 (0.02, 10.77) |
| High-grade endometrioid, N=60 | |||||||
| Absent (n=49) | 14 (28.6) | 1.00 | 1.00 | Absent (n=55) | 13 (23.6) | 1.00 | 1.00 |
| Present (n=5) | 0 (0.0) | --- | --- | Present (n=5) | 0 (0.0) | --- | --- |
| Serous, N=40 | |||||||
| Absent (n=28) | 13 (46.4) | 1.00 | 1.00 | Absent (n=32) | 14 (43.8) | 1.00 | 1.00 |
| Present (n=4) | 4 (100.0) | 2.62 (0.84, 8.21) | 1.14 (0.20, 6.53) | Present (n=8) | 8 (100.0) | 3.19 (1.32, 7.72) | 3.38 (0.87, 13.13) |
| Mixed epithelial, N=57 | |||||||
| Absent (n=44) | 7 (15.9) | 1.00 | 1.00 | Absent (n=48) | 7 (14.6) | 1.00 | 1.00 |
| Present (n=6) | 0 (0.0) | --- | --- | Present (n=9) | 2 (22.2) | 1.73 (0.36, 8.34) | 1.10 (0.19, 6.49) |
| Carcinosarcoma, N=29 | |||||||
| Absent (n=21) | 11 (52.4) | 1.00 | 1.00 | Absent (n=25) | 13 (52.0) | 1.00 | 1.00 |
| Present (n=1) | 1 (100.0) | 4.73 (0.53, 42.35) | --- | Present (n=4) | 3 (75.0) | 2.78 (0.76, 10.14) | 0.52 (0.04, 7.65) |
| Clear cell, N=9 | |||||||
| Absent (n=8) | 2 (25.0) | 1.00 | 1.00 | Absent (n=8) | 1 (12.5) | 1.00 | 1.00 |
| Present (n=0) | --- | --- | --- | Present (n=1) | 1 (100.0) | --- | --- |
1
Women with stage IV disease excluded from model
2
row percentage
3
Unadjusted HRs and 95% CIs
4
HRs and 95% CIs adjusted for age (<55, 55–64, ≥65) and FIGO 2009 stage (I, II, III, IV)